Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tuong Nguyen

Surgery Riverside, CA Medical Doctor

NPI 1831531565 CMS profile 1155957

7111 Indiana Ave Ste 100, Riverside, CA 92504

Open in the dashboard

General payments

$56,913

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tuong Nguyen of Riverside, CA is reported in the CMS Open Payments database as having received $56,913 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,878 38
2024 General $22,086 25
2023 General $22,226 18
2022 General $2,476 15
2021 General $892 19
2020 General $1,863 21
2019 General $3,492 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tuong Nguyen
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Tuong Nguyen were reported at $3,878. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Tuong Nguyen Surgery median Middle half National median
2019 $3,492 $253 $82–$1,521 $163
2020 $1,863 $131 $40–$706 $114
2021 $892 $168 $50–$904 $132
2022 $2,476 $224 $76–$1,218 $149
2023 $22,226 $253 $82–$1,255 $160
2024 $22,086 $279 $90–$1,381 $164
2025 $3,878 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $42,354 14 payments
  2. Endologix, Inc. $4,303 18 payments
  3. W. L. Gore & Associates, Inc. $2,574 27 payments
  4. Penumbra, Inc. $2,172 11 payments
  5. Cook Medical LLC $1,061 18 payments
  6. Cardiovascular Systems Inc. $811 12 payments
  7. Medtronic, Inc. $685 10 payments
  8. Bard Peripheral Vascular, Inc. $582 19 payments
  9. Medtronic Vascular, Inc. $554 18 payments
  10. Silk Road Medical, Inc. $316 4 payments
  11. Other $1,501 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $41,750 2 payments
  2. Food and Beverage $11,503 164 payments
  3. Travel and Lodging $2,156 9 payments
  4. Education $1,504 7 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $41,750 2 payments
  2. RUBY Coil $1,768 7 payments
  3. ENDOCROSS Device $1,681 3 payments
  4. Torus Stent Graft System $1,681 3 payments
  5. EXCLUDER AAA Endoprosthesis $1,428 10 payments
  6. Ovation $1,085 7 payments
  7. AFX $1,085 7 payments
  8. Alto Abdominal Stent Graft System $1,056 6 payments
  9. AURYON LASER SYSTEM 100-120 VAC Pad $604 12 payments
  10. CT THROMBECTOMY SYSTEM KIT $491 4 payments
  11. Other $8,562 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

281

Median for General Surgery: 59

Drug cost

$61,581

Median for General Surgery: $393

Branded share of claims

63.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 79 $48,264
Eliquis Apixaban Brand 18 $12,292
Clopidogrel Clopidogrel Bisulfate Brand 81 $435
Atorvastatin Calcium Generic 55 $329
Gabapentin Generic 27 $247
Lorazepam Generic 21 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$135,616

Medicare's payments for the services billed

Medicare patients

270

Average age 74

Services billed

643

131 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Chronic kidney disease 57%
Ischemic heart disease 51%
Arthritis 51%
Heart failure 41%
Atrial fibrillation 26%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record